COMPANY
Company Identity
COMPANY
Company Identity
LEADING GLOBAL R&D Innovator
CURACLE Co., Ltd. is introducing a new era, welcoming 150 years of happy and healthy life,
by developing global innovative new treatments for intractable diseases caused by aging and damaged blood vessels.
Embarking on a New Challenge, Miracle Cure, Leading Global Market
Open Healthy & Happy Living up to 150 years old
Present
Unmet Medical Needs
• Diabetic Retinopathy
• Macular Degeneration
• Ischemic Vascular Diseases
• Diabetic Nephropathy
• Cancer
• Non-alcoholic steatohepatitis (NASH)
• Stroke
• Inflammatory Bowel Disease (IBD)
Key Development
Age-Related Vascular Diseases
Intractable Metabolic Diseases
Targeted Therapy / Immunotherapy for Cancer
Present
Creative Scientific Discovery
Innovative Molecules
New Clinical Concept
• Vascular Normalization
• Prevention of Aging
• Restoration of Vascular Damage
• Maintenance of Mitochondrial Function
Novel Therapeutics
Leading rapidly growing present and future market
Global growth by develoing unparalleled platform technology and creating innovative new drugs
Strengthening market leadership through the continued success of pipelines and global partnerships
Growth stage
(2019-2020)
• Portfolio consisting of drug candidates and early phase clinical trials
• Completed Phase 2a clinical trial of CU01 & CU03
• Entered Phase 1 clinical trial of CU06
• Completed Series B financing
• Build relationship with domestic and foreign partners
• Completed technology assessment for special listings
Take-off Stage
(2021-2023)
• Add new innovative pipeline
• Initial Public Offering (IPO)
• Portfolio consisting of pre-clinical and late phase clinical trials
• Out-licensing and co-development with domestic and international pharmaceutical companies
• Creation of milestone profits
• Establishment of second laboratory (toxicity & efficacy evaluation)
• Addition of new innovative pipelines
Achieving VISION
(2024-)
• Establish unrivaled and innovative drug platform
• Launch internally developed drugs worldwide
• Global R&D innovator leader focused
on unmet medical needs